Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

–News Direct– By Jeremy Golden, Benzinga Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial…

View More Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

World One International Introduces SHII, the Cognitive Collaborator Welcoming a New Era of Interactive Intelligence Built on Factual Accuracy

Atlanta, GA, 3rd June 2024, ZEX PR WIRE, World One International, a leader in pioneering next-generation Cognitive Intelligence (CI) solutions, today unveils SHII, a groundbreaking cognitive…

View More World One International Introduces SHII, the Cognitive Collaborator Welcoming a New Era of Interactive Intelligence Built on Factual Accuracy